Identification
- Summary
Thiosulfuric acid is a sulfur donor used sequentially with sodium nitrite for the reversal of life-threatening acute cyanide poisoning. Also used to reduce the risk of ototoxicity associated with cisplatin.
- Brand Names
- Nithiodote, Pedmark, Seacalphyx
- Generic Name
- Thiosulfuric acid
- DrugBank Accession Number
- DB09499
- Background
Thiosulfuric acid is available in its salt forms sodium thiosulfate and sodium thiosulfate pentahydrate. Sodium thiosulfate is part of the World Health Organization’s list of essential medicines, and it has a variety of industrial uses, including food preservative, water de-chlorinator and paper pulp bleaching agent.1 Sodium thiosulfate is rapidly degraded in the stomach; therefore, it is normally administered through other routes, such as intravenous or topical.1 Sodium thiosulfate is approved for the treatment of acute cyanide poisoning5,6,2 and it is frequently used in conjunction with sodium nitrite (a salt form of nitrous acid). Sodium thiosulfate is also used to reduce the risk of ototoxicity associated with cisplatin.7 When administered 6 hours after cisplatin chemotherapy, Sodium thiosulfate leads to a lower incidence of cisplatin-induced hearing loss among children without affecting its effectiveness.3,4
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Thiosulfuric acid (DB09499)
- Weight
- Average: 114.144
Monoisotopic: 113.94453531 - Chemical Formula
- H2O3S2
- Synonyms
- Monosulfanemonosulfonic acid
- Sulfurothioic S-acid
Pharmacology
- Indication
Thiosulfuric acid (as sodium thiosulfate) is indicated for sequential intravenous use with sodium nitrite for the treatment of acute cyanide poisoning that is judged to be life-threatening.6 Sodium thiosulfate is also indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors in the US.7 In Europe, it is indicated for the same prevention of ototoxicity for patients 1 month of age to < 18 years old.8
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Prevention of Cisplatin ototoxicity •••••••••••• ••••••••• ••••••••••••• ••••••••• ••••• •••••• ••••••••• Used in combination to treat Cyanide poisoning Combination Product in combination with: Nitrous acid (DB09112) •••••••••••• ••••••••• Prevention of Ototoxicity from cisplatin chemotherapy •••••••••••• ••••••••••••• ••••••••• ••••• •••••• •••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Sodium thiosulfate doses of 20, 15 and 10 g/m2 deliver sodium loads of 162, 121 and 81 mmol/m2. One hour after infusion, the administration of sodium thiosulfate causes a transient increase in sodium of approximately 6 mmol/L; however, levels return to baseline 18 to 24 hours after infusion.7 The pharmacodynamics of sodium thiosulfate as an antidote for the treatment of acute cyanide poisoning were evaluated by measuring the rate of conversion of cyanide to thiocyanate. Pretreatment with sodium thiosulfate to achieve a steady state level of 2 µmol/mL increased the rate of conversion of cyanide to thiocyanate over 30-fold in dogs.6 The use of sodium thiosulfate may cause hypersensitivity reactions and lead to hypernatremia and hypokalemia. It may also lead to nausea and vomiting.7
- Mechanism of action
When administered with sodium nitrate, sodium thiosulfate acts as an antidote for the treatment of acute cyanide poisoning.6 Cyanide has a high affinity for cytochrome a3, a component of the cytochrome c oxidase complex in mitochondria. By binding and inhibiting cytochrome a3, cyanide prevents cells from using oxygen and forces anaerobic metabolism, inhibiting cellular respiration and resulting in lactic acidosis and cytotoxic hypoxia. Sodium nitrite reacts with hemoglobin to form methemoglobin, which competes with cytochrome a3 for the cyanide ion. Cyanide binds to methemoglobin to form cyanmethemoglobin, a nontoxic compound, and restore cytochrome oxidase activity. When cyanide dissociates from methemoglobin, sodium thiosulfate acts as a sulfur donor for the endogenous sulfur transferase enzyme and facilitates its conversion to thiocyanate, a less toxic ion.6
Sodium thiosulfate can also reduce the risk of ototoxicity associated with cisplatin. Pediatric patients treated with cisplatin have a high risk of developing ototoxicity, possibly due to a combination of reactive oxygen species (ROS) production and direct alkylation of DNA that leads to cell death.7 Sodium thiosulfate interacts with cisplatin to form inactive platinum species. It can also enter cells via the sodium sulfate cotransporter 2 to increase antioxidant glutathione levels and inhibit intracellular oxidative stress. Although a mechanism of action has not been fully elucidated, both activities are thought to reduce the risk of ototoxicity.7
- Absorption
Sodium thiosulfate taken orally is not systemically absorbed. Most of the thiosulfate is oxidized to sulfate or is incorporated into endogenous sulphur compounds; a small proportion is excreted through the kidneys.6 In pediatric patients given the recommended intravenous dose of sodium thiosulfate, the Cmax of thiosulfate was 13 ± 1.2 mM, and increased proportionally to dose over the range of 4 g/m2 to 20 g/m2. Thiosulfate accumulation is not expected following the intravenous administration of sodium thiosulfate on 2 consecutive days.7
- Volume of distribution
Thiosulfate has a mean volume of distribution of 0.23 L/kg.7
- Protein binding
Sodium thiosulfate does not bind to human plasma proteins.7
- Metabolism
Thiosulfate sulfur transferase and thiosulfate reductase metabolize thiosulfate to form sulfite, which is oxidized to sulfate.7
- Route of elimination
Approximately 20-50% of exogenously administered sodium thiosulfate is eliminated by the kidneys.6,7 More than 95% of the thiosulfate eliminated in urine is excreted within the first 4 hours after administration.7 When used as an antidote to cyanide poisoning, sodium thiosulfate is eliminated as thiocyanate, a relatively nontoxic compound. Thiocyanate is also excreted in urine at a rate inversely proportional to creatinine clearance.6
- Half-life
The half-life of thiosulfate administered intravenously (1 g sodium thiosulfate) was approximately 20 minutes. However, higher doses may increase this value. In healthy men given 150 mg/kg of sodium thiosulfate, the elimination half-life was 182 minutes.6
- Clearance
In patients with fully developed renal function (1 year old approximately), the mean total clearance of thiosulfate is 2.2 mL/min/kg.7
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
The effects in humans of large doses of sodium thiosulfate have not been thoroughly studied. Sodium thiosulfate administered orally (3 g per day) for 1-2 weeks resulted in reductions in room air arterial oxygen saturation to as low as 75%. One week after discontinuation, subjects returned to baseline oxygen saturations. A single dose of 20 mL of 10% sodium thiosulfate administered intravenously did not have an effect on oxygen saturation.6
In rats, the oral LD50 of sodium thiosulfate pentahydrate is 5000 mg/kg.[L43327] The carcinogenic activity of sodium thiosulfate has not been evaluated. An in vitro bacterial reverse mutation assay showed that sodium thiosulfate was not mutagenic in the absence nor presence of metabolic activation.7
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAmitriptyline The metabolism of Amitriptyline can be increased when combined with Thiosulfuric acid. Antipyrine The metabolism of Antipyrine can be increased when combined with Thiosulfuric acid. Apomorphine The metabolism of Apomorphine can be increased when combined with Thiosulfuric acid. Artemether The metabolism of Artemether can be increased when combined with Thiosulfuric acid. Asunaprevir The metabolism of Asunaprevir can be increased when combined with Thiosulfuric acid. - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Sodium thiosulfate L0IYT1O31N 7772-98-7 AKHNMLFCWUSKQB-UHFFFAOYSA-L Sodium thiosulfate pentahydrate HX1032V43M 10102-17-7 PODWXQQNRWNDGD-UHFFFAOYSA-L - International/Other Brands
- Pedmark (Fennec Pharmaceuticals,)
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Pedmark Injection, solution 12.5 g/100mL Intravenous Fennec Pharmaceuticals Inc. 2022-10-03 Not applicable US 
Pedmarqsi Injection, solution 80 mg/ml Intravenous Fennec Pharmaceuticals (Eu) Limited 2023-06-09 Not applicable EU 
Seacalphyx Solution 250 mg / mL Intravenous Seaford Pharmaceuticals Inc 2013-01-08 Not applicable Canada 
Sodium Thiosulfate Injection, solution 250 mg/1mL Intravenous Hope Pharmaceuticals 2012-02-14 Not applicable US Sodium Thiosulfate Inj 25% USP Liquid 250 mg / mL Intravenous David Bull Laboratories (Pty) Ltd. 1991-12-31 1998-08-13 Canada - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Oligostim Soufre Tablet 0.015 mg Oral Dolisos Laboratoires S.A. 1998-06-11 2007-08-01 Canada วีเนีย Powder 15 g บริษัท วิทยาศรม จำกัด 1991-10-18 Not applicable Thailand 
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Adasept Acne Gel Sodium thiosulfate (8 %) + Salicylic acid (2 %) + Triclosan (0.5 %) Lotion Topical Odan Laboratories Ltd 1974-12-31 Not applicable Canada Nithiodote Sodium thiosulfate pentahydrate (250 mg/1mL) + Sodium nitrite (30 mg/1mL) Injection, solution; Kit Intravenous Hope Pharmaceuticals 2011-01-14 Not applicable US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Sodium polysulthionate and folic acid Sodium thiosulfate pentahydrate (1.8 mg/1) + Folic acid (1 mg/1) + Octasulfur (388 mg/1) + Sodium sulfate decahydrate (8 mg/1) Capsule Oral Solubiomix 2016-08-24 2017-10-16 US Sodium polysulthionate, 5-methyltetrahydrofolate Sodium thiosulfate pentahydrate (.45 g/100g) + Levomefolic acid (.125 g/100g) + Octasulfur (97 g/100g) + Sodium sulfate decahydrate (2 g/100g) Powder Oral; Topical Solubiomix 2015-07-21 2016-01-12 US Sodium Polysulthionate, 5-mthf Sodium thiosulfate pentahydrate (1.8 mg/1) + 5-methyltetrahydrofolic acid (.5 mg/1) + Octasulfur (388 mg/1) + Sodium sulfate decahydrate (8 mg/1) Capsule Oral Solubiomix 2016-01-09 2016-01-12 US Sodum Thiosulfate Sodium thiosulfate pentahydrate (100 mg/1mL) Injection, solution Intravenous American Regent 1990-09-30 2012-11-28 US Sodum Thiosulfate Sodium thiosulfate pentahydrate (250 mg/1mL) Injection, solution Intravenous American Regent 1990-09-30 2012-11-28 US
Categories
- Drug Categories
- Acids
- Anti-Infective Agents
- Antidotes
- Antioxidants
- Biological Factors
- Chelating Agents
- Compounds used in a research, industrial, or household setting
- Cytochrome P-450 CYP2B6 Inducers
- Cytochrome P-450 CYP2B6 Inducers (strength unknown)
- Cytochrome P-450 Enzyme Inducers
- Minerals
- Protective Agents
- Sequestering Agents
- Sulfates
- Sulfur Acids
- Sulfur Compounds
- Sulfuric Acids
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of inorganic compounds known as non-metal thiosulfates. These are inorganic non-metallic compounds containing a thiosulfate as its largest oxoanion.
- Kingdom
- Inorganic compounds
- Super Class
- Homogeneous non-metal compounds
- Class
- Non-metal oxoanionic compounds
- Sub Class
- Non-metal thiosulfates
- Direct Parent
- Non-metal thiosulfates
- Alternative Parents
- Inorganic sulfides / Inorganic oxides
- Substituents
- Inorganic oxide / Inorganic sulfide / Non-metal thiosulfate
- Molecular Framework
- Not Available
- External Descriptors
- thiosulfuric acid (CHEBI:29279)
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 7K79Y2EKKP
- CAS number
- 13686-28-7
- InChI Key
- DHCDFWKWKRSZHF-UHFFFAOYSA-N
- InChI
- InChI=1S/H2O3S2/c1-5(2,3)4/h(H2,1,2,3,4)
- IUPAC Name
- dihydroxy-1lambda6-disulfen-1-one
- SMILES
- OS(O)(=O)=S
References
- Synthesis Reference
Sherman, C., et al. (2016). Sodium thiosulfate-containing pharmaceutical compositions (U.S. Patent No. 2016/0235782 A1). U.S. Patent and Trademark Office. https://patentimages.storage.googleapis.com/0c/2a/58/edc43adab43077/US20160235782A1.pdf
- General References
- Zhang MY, Dugbartey GJ, Juriasingani S, Sener A: Hydrogen Sulfide Metabolite, Sodium Thiosulfate: Clinical Applications and Underlying Molecular Mechanisms. Int J Mol Sci. 2021 Jun 16;22(12). pii: ijms22126452. doi: 10.3390/ijms22126452. [Article]
- Bebarta VS, Brittain M, Chan A, Garrett N, Yoon D, Burney T, Mukai D, Babin M, Pilz RB, Mahon SB, Brenner M, Boss GR: Sodium Nitrite and Sodium Thiosulfate Are Effective Against Acute Cyanide Poisoning When Administered by Intramuscular Injection. Ann Emerg Med. 2017 Jun;69(6):718-725.e4. doi: 10.1016/j.annemergmed.2016.09.034. Epub 2016 Dec 29. [Article]
- Freyer DR, Chen L, Krailo MD, Knight K, Villaluna D, Bliss B, Pollock BH, Ramdas J, Lange B, Van Hoff D, VanSoelen ML, Wiernikowski J, Neuwelt EA, Sung L: Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017 Jan;18(1):63-74. doi: 10.1016/S1470-2045(16)30625-8. Epub 2016 Dec 1. [Article]
- Brock PR, Maibach R, Childs M, Rajput K, Roebuck D, Sullivan MJ, Laithier V, Ronghe M, Dall'Igna P, Hiyama E, Brichard B, Skeen J, Mateos ME, Capra M, Rangaswami AA, Ansari M, Rechnitzer C, Veal GJ, Covezzoli A, Brugieres L, Perilongo G, Czauderna P, Morland B, Neuwelt EA: Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss. N Engl J Med. 2018 Jun 21;378(25):2376-2385. doi: 10.1056/NEJMoa1801109. [Article]
- Medsafe New Zealand Approved Drug Products: DBL sodium thiosulfate solution for injection [Link]
- FDA Approved Drug Products: NITHIODOTE (sodium nitrite and sodium thiosulfate) injection for intravenous infusion [Link]
- FDA Approved Drug Products: PEDMARK (sodium thiosulfate) injection for intravenous use [Link]
- EMA Approved Drug Products: Pedmarqsi (sodium thiosulfate) injection for intravenous injection [Link]
- External Links
- Human Metabolome Database
- HMDB0000257
- KEGG Compound
- C05529
- PubChem Compound
- 24478
- PubChem Substance
- 347827866
- ChemSpider
- 22886
- ChEBI
- 5587
- ChEMBL
- CHEMBL1208642
- ZINC
- ZINC000008214573
- Wikipedia
- Thiosulfuric_acid
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Terminated Treatment Cutaneous calcification 1 3 Active Not Recruiting Treatment Medulloblastomas 1 3 Completed Supportive Care Brain Neoplasm / Central Nervous System Neoplasm / Extragonadal Germ Cell Tumor / Liver Cancer / Neuroblastoma (NB) / Ototoxicity / Ovarian Cancer / Pediatric Germ Cell Tumor / Sarcomas 1 3 Completed Treatment Liver Cancer / Ototoxicity 1 3 Recruiting Treatment Calciphylaxis 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Lotion Topical Injection, solution; kit Intravenous Tablet Oral 0.015 mg Injection, solution Intravenous 12.5 g/100mL Injection, solution Intravenous 80 mg/ml Solution Intravenous 250 mg / mL Injection, solution, concentrate Intravenous Liquid Intravenous 250 mg / mL Injection, solution Intravenous 100 mg/1mL Injection, solution Intravenous 250 mg/1mL Powder Oral Solution Intravenous 200 mg Capsule Oral Powder Oral; Topical Powder 15 g Injection, solution Intravenous 262.5 mg/1ml - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US8496973 No 2013-07-30 2031-03-29 US US8568793 No 2013-10-29 2031-12-24 US US9585912 No 2017-03-07 2031-03-29 US US9345724 No 2016-05-24 2031-03-29 US US9687506 No 2017-06-27 2031-12-24 US US10479686 No 2019-11-19 2031-03-29 US US10596190 No 2020-03-24 2038-01-05 US US11291728 No 2019-07-01 2039-07-01 US US11510984 No 2019-07-01 2039-07-01 US US11617793 No 2019-07-01 2039-07-01 US US11753301 No 2010-02-10 2030-02-10 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 48 °C Sigma-Aldrich: Sodium thiosulfate SDS (https://www.sigmaaldrich.com/CA/en/sds/SIGALD/217263) boiling point (°C) 100°C ScholAR Chemistry: Sodium thiosulfate SDS (https://www.mccsd.net/cms/lib/NY02208580/Centricity/Shared/Material%20Safety%20Data%20Sheets%20_MSDS_/MSDS%20Sheets_Sodium_Thiosulfate_Anhydrous_703_00.pdf) water solubility 210 g/L Sigma-Aldrich: Sodium thiosulfate SDS (https://www.sigmaaldrich.com/CA/en/sds/SIGALD/217263) - Predicted Properties
Property Value Source logP 0.048 Chemaxon pKa (Strongest Acidic) 2.7 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 57.53 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 21.76 m3·mol-1 Chemaxon Polarizability 8.51 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-03di-2900000000-0340aa179a944cddc03f Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-03di-0900000000-9b392ce35f8d17472a4f Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-03di-0900000000-8713d6562312e043b633 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-03di-2900000000-354647bf0c281581f176 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-03di-0900000000-2c260178b79a63eadae6 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0002-9300000000-2fd3cffde331cad1dd43 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-03di-0900000000-bfc4d410b67f38a234f9 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 101.8675725 predictedDarkChem Lite v0.1.0 [M-H]- 101.8686725 predictedDarkChem Lite v0.1.0 [M-H]- 126.323906 predictedDeepCCS 1.0 (2019) [M+H]+ 129.12137 predictedDeepCCS 1.0 (2019) [M+Na]+ 137.25946 predictedDeepCCS 1.0 (2019)
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Substrate
- Curator comments
- Processed as sodium thiosulfate.
- General Function
- Thiosulfate sulfurtransferase activity
- Specific Function
- Formation of iron-sulfur complexes, cyanide detoxification or modification of sulfur-containing enzymes. Other thiol compounds, besides cyanide, can act as sulfur ion acceptors. Also has weak merca...
- Gene Name
- TST
- Uniprot ID
- Q16762
- Uniprot Name
- Thiosulfate sulfurtransferase
- Molecular Weight
- 33428.69 Da
References
- FDA Approved Drug Products: PEDMARK (sodium thiosulfate) injection for intravenous use [Link]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- Curator comments
- Processed as sodium thiosulfate.
- General Function
- Thiosulfate:glutathione sulfurtransferase (TST) required to produce S-sulfanylglutathione (GSS(-)), a central intermediate in hydrogen sulfide metabolism (PubMed:24981631). Provides the link between the first step in mammalian H(2)S metabolism performed by the sulfide:quinone oxidoreductase (SQOR) which catalyzes the conversion of H(2)S to thiosulfate, and the sulfur dioxygenase (SDO) which uses GSS(-) as substrate (PubMed:24981631). The thermodynamic coupling of the irreversible SDO and reversible TST reactions provides a model for the physiologically relevant reaction with thiosulfate as the sulfane donor (PubMed:24981631).
- Specific Function
- Dna-binding transcription factor activity, rna polymerase ii-specific
- Gene Name
- TSTD1
- Uniprot ID
- Q8NFU3
- Uniprot Name
- Thiosulfate:glutathione sulfurtransferase
- Molecular Weight
- 12530.1 Da
References
- FDA Approved Drug Products: PEDMARK (sodium thiosulfate) injection for intravenous use [Link]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inducer
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2B6
- Uniprot ID
- P20813
- Uniprot Name
- Cytochrome P450 2B6
- Molecular Weight
- 56277.81 Da
References
- FDA Approved Drug Products: PEDMARK (sodium thiosulfate) injection for intravenous use [Link]
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Binder
- General Function
- Sodium/sulfate cotransporter that mediates sulfate reabsorption in the high endothelial venules (HEV).
- Specific Function
- Sodium
- Gene Name
- SLC13A4
- Uniprot ID
- Q9UKG4
- Uniprot Name
- Solute carrier family 13 member 4
- Molecular Weight
- 69357.885 Da
References
- FDA Approved Drug Products: PEDMARK (sodium thiosulfate) injection for intravenous use [Link]
Drug created at November 30, 2015 19:10 / Updated at February 20, 2024 23:55